Calliope Holingue1,2, Carol Newill1, Li-Ching Lee1,2,3, Pankaj J Pasricha4, M Daniele Fallin1,2. 1. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 2. Johns Hopkins Bloomberg School of Public Health, Wendy Klag Center for Autism and Developmental Disabilities, Baltimore, MD. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 4. Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Center for Neurogastroenterology, Baltimore, MD.
Abstract
There is no standard approach to measuring GI symptoms in individuals with ASD, despite postulated interactions. The objectives of this study were to (a) describe the range of GI symptom ascertainment approaches in studies of ASD, (b) describe the range of prevalence estimates across studies, and (c) assess associations between ascertainment approach and prevalence estimates. Studies published from 1/1/1980 to 1/31/2017 were collected via PubMed. Eligibility included studies with at least ten individuals with ASD that measured GI symptoms or conditions. We excluded review and hypothesis papers. We extracted information on study design, GI symptom ascertainment method, demographics, and ASD diagnostic criteria. From a subset of studies, we extracted GI symptom estimates. Out of a possible 386 titles, 144 were included. The prevalence range for constipation was 4.3-45.5% (median 22%), for diarrhea was 2.3-75.6% (median 13.0%), and for any or more than one symptom was 4.2-96.8% (median 46.8%). GI symptoms differed significantly by age of individuals, primary goal of study, study design, study sample, and who reported symptoms (P < .05). Due to small sample size, we were not able to test for associations between every GI symptom and study characteristic of interest, or examine associations between GI symptoms and intellectual or verbal disability. Studies used a broad range of methods to ascertain GI symptoms in ASD. GI symptoms varied widely across these studies, with significant differences by study characteristics. Our findings highlight the need for a reliable, valid GI assessment tool to be used consistently across studies of ASD. Autism Res 2018, 11: 24-36.
There is no standard approach to measuring GI symptoms in individuals with ASD, despite postulated interactions. The objectives of this study were to (a) describe the range of GI symptom ascertainment approaches in studies of ASD, (b) describe the range of prevalence estimates across studies, and (c) assess associations between ascertainment approach and prevalence estimates. Studies published from 1/1/1980 to 1/31/2017 were collected via PubMed. Eligibility included studies with at least ten individuals with ASD that measured GI symptoms or conditions. We excluded review and hypothesis papers. We extracted information on study design, GI symptom ascertainment method, demographics, and ASD diagnostic criteria. From a subset of studies, we extracted GI symptom estimates. Out of a possible 386 titles, 144 were included. The prevalence range for constipation was 4.3-45.5% (median 22%), for diarrhea was 2.3-75.6% (median 13.0%), and for any or more than one symptom was 4.2-96.8% (median 46.8%). GI symptoms differed significantly by age of individuals, primary goal of study, study design, study sample, and who reported symptoms (P < .05). Due to small sample size, we were not able to test for associations between every GI symptom and study characteristic of interest, or examine associations between GI symptoms and intellectual or verbal disability. Studies used a broad range of methods to ascertain GI symptoms in ASD. GI symptoms varied widely across these studies, with significant differences by study characteristics. Our findings highlight the need for a reliable, valid GI assessment tool to be used consistently across studies of ASD. Autism Res 2018, 11: 24-36.
Authors: E Del Giudice; A Staiano; G Capano; A Romano; L Florimonte; E Miele; C Ciarla; A Campanozzi; A F Crisanti Journal: Brain Dev Date: 1999-07 Impact factor: 1.961
Authors: M M Tabbers; C DiLorenzo; M Y Berger; C Faure; M W Langendam; S Nurko; A Staiano; Y Vandenplas; M A Benninga Journal: J Pediatr Gastroenterol Nutr Date: 2014-02 Impact factor: 2.839
Authors: Martina Sgritta; Sean W Dooling; Shelly A Buffington; Eric N Momin; Michael B Francis; Robert A Britton; Mauro Costa-Mattioli Journal: Neuron Date: 2018-12-03 Impact factor: 17.173
Authors: Katherine R Bellesheim; Lynn Cole; Daniel L Coury; Larry Yin; Susan E Levy; Meghan A Guinnee; Kirsten Klatka; Beth A Malow; Terry Katz; Jane Taylor; Kristin Sohl Journal: Pediatrics Date: 2018-08-14 Impact factor: 7.124
Authors: Heba J Sabbagh; Basma A Al-Jabri; Malek A Alsulami; Lutfi A Hashem; Ala A Aljubour; Rana A Alamoudi Journal: Saudi Med J Date: 2021-04 Impact factor: 1.484